ALX Oncology (ALXO) Competitors $1.12 -0.01 (-0.45%) Closing price 02/21/2025 03:59 PM EasternExtended Trading$1.12 0.00 (0.00%) As of 02/21/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends ALXO vs. LFCR, LRMR, CGEN, AMRN, CTNM, VIRI, OCGN, DRUG, MOLN, and ZYBTShould you be buying ALX Oncology stock or one of its competitors? The main competitors of ALX Oncology include Lifecore Biomedical (LFCR), Larimar Therapeutics (LRMR), Compugen (CGEN), Amarin (AMRN), Contineum Therapeutics (CTNM), Virios Therapeutics (VIRI), Ocugen (OCGN), Bright Minds Biosciences (DRUG), Molecular Partners (MOLN), and Zhengye Biotechnology (ZYBT). These companies are all part of the "pharmaceutical products" industry. ALX Oncology vs. Lifecore Biomedical Larimar Therapeutics Compugen Amarin Contineum Therapeutics Virios Therapeutics Ocugen Bright Minds Biosciences Molecular Partners Zhengye Biotechnology ALX Oncology (NASDAQ:ALXO) and Lifecore Biomedical (NASDAQ:LFCR) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, profitability, analyst recommendations, institutional ownership, media sentiment, community ranking, dividends, valuation and earnings. Which has higher earnings and valuation, ALXO or LFCR? Lifecore Biomedical has higher revenue and earnings than ALX Oncology. Lifecore Biomedical is trading at a lower price-to-earnings ratio than ALX Oncology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioALX OncologyN/AN/A-$160.80M-$2.98-0.37Lifecore Biomedical$128.26M1.62$12.01M-$0.56-10.02 Do analysts recommend ALXO or LFCR? ALX Oncology presently has a consensus price target of $3.05, suggesting a potential upside of 173.54%. Lifecore Biomedical has a consensus price target of $8.00, suggesting a potential upside of 42.60%. Given ALX Oncology's stronger consensus rating and higher possible upside, equities analysts plainly believe ALX Oncology is more favorable than Lifecore Biomedical.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ALX Oncology 0 Sell rating(s) 3 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50Lifecore Biomedical 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33 Is ALXO or LFCR more profitable? ALX Oncology has a net margin of 0.00% compared to Lifecore Biomedical's net margin of -12.52%. ALX Oncology's return on equity of -93.02% beat Lifecore Biomedical's return on equity.Company Net Margins Return on Equity Return on Assets ALX OncologyN/A -93.02% -70.67% Lifecore Biomedical -12.52%-315.23%-12.74% Do institutionals & insiders have more ownership in ALXO or LFCR? 98.0% of ALX Oncology shares are held by institutional investors. Comparatively, 83.4% of Lifecore Biomedical shares are held by institutional investors. 33.4% of ALX Oncology shares are held by insiders. Comparatively, 28.2% of Lifecore Biomedical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Which has more volatility and risk, ALXO or LFCR? ALX Oncology has a beta of 0.96, meaning that its stock price is 4% less volatile than the S&P 500. Comparatively, Lifecore Biomedical has a beta of 0.96, meaning that its stock price is 4% less volatile than the S&P 500. Does the media prefer ALXO or LFCR? In the previous week, ALX Oncology had 1 more articles in the media than Lifecore Biomedical. MarketBeat recorded 1 mentions for ALX Oncology and 0 mentions for Lifecore Biomedical. ALX Oncology's average media sentiment score of 0.00 equaled Lifecore Biomedical'saverage media sentiment score. Company Overall Sentiment ALX Oncology Neutral Lifecore Biomedical Neutral Does the MarketBeat Community favor ALXO or LFCR? ALX Oncology received 49 more outperform votes than Lifecore Biomedical when rated by MarketBeat users. Likewise, 64.20% of users gave ALX Oncology an outperform vote while only 25.00% of users gave Lifecore Biomedical an outperform vote. CompanyUnderperformOutperformALX OncologyOutperform Votes5264.20% Underperform Votes2935.80% Lifecore BiomedicalOutperform Votes325.00% Underperform Votes975.00% SummaryALX Oncology beats Lifecore Biomedical on 10 of the 14 factors compared between the two stocks. Get ALX Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for ALXO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALXO vs. The Competition Export to ExcelMetricALX OncologyPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$58.81M$7.06B$5.84B$9.14BDividend YieldN/A2.76%4.76%3.85%P/E Ratio-0.372.9318.2614.95Price / SalesN/A281.18434.4770.76Price / CashN/A65.9238.4235.17Price / Book0.296.717.644.65Net Income-$160.80M$138.11M$3.18B$245.69M7 Day Performance1.36%-2.54%-1.95%-2.68%1 Month Performance-38.06%-2.00%-0.23%-2.16%1 Year Performance-93.05%-5.04%16.69%12.90% ALX Oncology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALXOALX Oncology3.2607 of 5 stars$1.12-0.4%$3.05+173.5%-93.0%$59.07MN/A-0.3740LFCRLifecore Biomedical2.6544 of 5 stars$5.87-0.7%$8.00+36.4%-30.1%$217.22M$128.26M-10.48690LRMRLarimar Therapeutics1.5761 of 5 stars$3.39-2.2%$20.13+494.5%-73.5%$216.00MN/A-2.9430CGENCompugen2.0013 of 5 stars$2.42-6.0%$4.00+65.5%-11.9%$215.69M$33.46M120.8570AMRNAmarin0.3188 of 5 stars$0.53-3.0%N/A-49.4%$215.60M$306.91M-5.83360CTNMContineum Therapeutics2.9162 of 5 stars$8.28-1.6%$29.25+253.4%N/A$213.37M$50M0.0031News CoverageVIRIVirios TherapeuticsN/A$10.74-9.1%$3.00-72.1%+1,411.6%$206.83MN/A-39.785OCGNOcugen1.6248 of 5 stars$0.71-0.6%$5.67+700.4%-35.8%$206.26M$6.04M-3.9380Positive NewsDRUGBright Minds Biosciences4.1388 of 5 stars$46.39+5.5%$84.33+81.8%+1,829.8%$205.53MN/A-92.79N/AAnalyst ForecastAnalyst RevisionNews CoverageMOLNMolecular Partners0.1344 of 5 stars$5.07+2.1%N/A+8.6%$204.79M$7.84M-2.36180News CoverageGap UpZYBTZhengye BiotechnologyN/A$4.30+2.1%N/AN/A$202.83MN/A0.00N/AQuiet Period ExpirationGap Down Related Companies and Tools Related Companies Lifecore Biomedical Competitors Larimar Therapeutics Competitors Compugen Competitors Amarin Competitors Contineum Therapeutics Competitors Virios Therapeutics Competitors Ocugen Competitors Bright Minds Biosciences Competitors Molecular Partners Competitors Zhengye Biotechnology Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ALXO) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon Takes Aim at Social SecurityElon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredNvidia’s Next Big Move Comes on Feb. 26Nvidia isn't the only company that benefits greatly from these earnings calls. That's because a handful of ...Weiss Ratings | SponsoredThe Real Hillbilly ElegyThe mountains of Appalachia are incredible to behold. Spanning thousands of miles across Alabama, Kentucky...Porter & Company | SponsoredMajor AI announcement for 2025BIG NEWS: “Market Wizard” Larry Benedict Releases a Whole New Way to Trade AI StocksBrownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ALX Oncology Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ALX Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
